Laboratorios Farmaceuticos Rovi (MEX:ROVIN) Current Deferred Revenue: MXN0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:ROVIN Laboratorios Farmaceuticos Rovi SA MEX:ROVIN
81 GF Score
Price MXN1,168.82
GF Value MXN1,103.32
! 2 Warning Signs
View Full Analysis

What is Laboratorios Farmaceuticos Rovi Current Deferred Revenue?

Laboratorios Farmaceuticos Rovi MEX:ROVIN 81 Current Deferred Revenue is MXN0 Mil as of Jun. 2026. GuruFocus rates MEX:ROVIN with a GF Score™ of 81/100 and a GF Value™ of MXN1,103.32. The stock has 2 warning signs investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Laboratorios Farmaceuticos Rovi's current deferred revenue for the quarter that ended in Jun. 2026 was MXN0 Mil.

Laboratorios Farmaceuticos Rovi Current Deferred Revenue Related Terms

Laboratorios Farmaceuticos Rovi Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Laboratorios Farmaceuticos Rovi's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Laboratorios Farmaceuticos Rovi Current Deferred Revenue Chart

Laboratorios Farmaceuticos Rovi Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Deferred Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Laboratorios Farmaceuticos Rovi Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
MEX:ROVIN
81GF Score
Laboratorios Farmaceuticos Rovi SA MEX:ROVIN
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of MXN0 Mil mean?
Laboratorios Farmaceuticos Rovi (MEX:ROVIN) has a Current Deferred Revenue of MXN0 Mil as of Jun. 2026. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Laboratorios Farmaceuticos Rovi and its competitors.
Is Laboratorios Farmaceuticos Rovi's Current Deferred Revenue too high?
Laboratorios Farmaceuticos Rovi's current Current Deferred Revenue is MXN0 Mil. Overall, Laboratorios Farmaceuticos Rovi has a GF Score™ of 81/100, reflecting its overall financial health beyond just this single metric.
How does Laboratorios Farmaceuticos Rovi's Current Deferred Revenue compare to ZTS and UTHR?
Laboratorios Farmaceuticos Rovi's Current Deferred Revenue of MXN0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Drug Manufacturers company?
A good Current Deferred Revenue depends on the Drug Manufacturers industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Laboratorios Farmaceuticos Rovi and its competitors. Laboratorios Farmaceuticos Rovi's current Current Deferred Revenue is MXN0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Laboratorios Farmaceuticos Rovi stock overvalued right now?
Laboratorios Farmaceuticos Rovi (MEX:ROVIN) has a current Current Deferred Revenue of MXN0 Mil. The stock's GF Value™ is MXN1,103.32, compared to a current price of MXN1,168.82 — trading 5.9% above its estimated fair value. The current Current Deferred Revenue is MXN0 Mil. Laboratorios Farmaceuticos Rovi's overall GF Score™ is 81/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For Laboratorios Farmaceuticos Rovi (MEX:ROVIN), the current Current Deferred Revenue is MXN0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Laboratorios Farmaceuticos Rovi (MEX:ROVIN) Overvalued in 2026?

Based on GuruFocus' analysis, Laboratorios Farmaceuticos Rovi stock appears to be overvalued. The current stock price of MXN1,168.82 is trading 5.9% above its estimated GF Value™ of MXN1,103.32.

Key valuation signals for MEX:ROVIN:

  • Current Deferred Revenue: MXN0 Mil
  • GF Value™: MXN1,103.32 vs. price of MXN1,168.82 (5.9% above fair value)
  • GF Score™: 81/100 with 2 warning signs

No single metric tells the full story. See the MEX:ROVIN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Laboratorios Farmaceuticos Rovi Business Description

Address Julian Camarillo, 35, Madrid, ESP, 28037
Laboratorios Farmaceuticos Rovi SA is a biotechnology company engaged in the research, development, manufacturing, and marketing of small molecule and specialty biologic drugs. The company has a diversified portfolio of products that it markets in Spain through its specialized sales force of specialist physicians, hospitals and pharmacies. Laboratorios' research and development pipeline is focused on the expansion of applications, indications, and alternative mechanisms of action for heparin-derived products. The company aims to obtain new pharmaceutical products that enable the regular administration of formulations that are administered daily in chronic and prolonged treatments. Its two segments are Manufacturing and Marketing.
81GF Score

Get the complete analysis for MEX:ROVIN

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN1,168.82
Price
MXN1,103.32
GF Value